Repligen Corporation (RGEN) Market Cap & Valuation Ratios
Repligen Corporation (RGEN) has a market cap of $10.0B, a trailing P/E of 242.4 and a price-to-sales ratio of 12.7, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RGENRepligen CorporationFollow RGEN — free
—
Price chart with a free account
- Market cap
- 10.0B
- P/E TTM
- 242.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Peers
medical instruments & supplies · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RGEN | 10.0 | 242.4 | 12.4 | 67.8 | 1.1% | +16% | 8% | 3% |
| SOLV | 15 | — | 2.3 | 7.4 | -0.8% | -0.9% | 25% | 17% |
| BAX | 13 | — | 1.8 | 30.0 | 6.2% | +5% | -2% | -2% |
| AVTR | 12 | — | 2.3 | 128.6 | 3.9% | -2% | -5% | -3% |
| COO | 12 | — | 3.3 | 15.1 | 5.8% | +5% | 13% | 3% |
| ALGN | 11 | 26.9 | 2.4 | 12.3 | 5.8% | +4% | 13% | 13% |
| ATR | 8.0 | 22.8 | 2.3 | 11.7 | 3.9% | +9% | 12% | 10% |
| BLCO | 6.2 | — | 2.1 | 15.0 | 2.2% | +9% | 6% | 2% |
| TFX | 5.8 | — | 3.7 | 43.0 | 2.9% | +31% | 2% | 0.6% |
| MMSI | 5.6 | 38.4 | 3.7 | 18.0 | 3.6% | +10% | 13% | 8% |
| MMED | 5.2 | — | 1.5 | — | -6.1% | +14% | -5% | -5% |
| Median of these 10 | 26.9 | 2.3 | 15.1 | 3.8% | +7% | 9% | 3% |
P/E 242.4 vs. a peer median of 26.9; EV/Sales 12.4 vs. 2.3. RGEN's own P/E sits at the 75th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesSOLV and BAX and AVTR and COO and BLCO and TFX and MMED have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Repligen Corporation — questions
- What is Repligen Corporation's market cap?
- $10.0B.
- What is Repligen Corporation's P/E ratio?
- 242.4 on trailing twelve-month earnings to 2026-06-30.
- What is Repligen Corporation's price-to-sales ratio?
- 12.7.
Every figure on this page comes from Repligen Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.